Measurement and Clinical Significance of Lipid Peroxidation as a Biomarker of Oxidative Stress: Oxidative Stress in Diabetes, Atherosclerosis, and Chronic Inflammation

Radi, 2013, Peroxynitrite, a stealthy biological oxidant, J. Biol. Chem., 288, 26464, 10.1074/jbc.R113.472936

Lushchak, 2014, Free radicals, reactive oxygen species, oxidative stress and its classification, Chem.-Biol. Interact., 224, 164, 10.1016/j.cbi.2014.10.016

McCord, 2000, The evolution of free radicals and oxidative stress, Am. J. Med., 108, 652, 10.1016/S0002-9343(00)00412-5

Li, 2015, The role of oxidative stress and antioxidants in liver diseases, Int. J. Mol. Sci., 16, 26087, 10.3390/ijms161125942

Maritim, 2003, Diabetes, oxidative stress, and antioxidants: A review, J. Biochem. Mol. Toxicol., 17, 24, 10.1002/jbt.10058

Bonomini, 2008, Atherosclerosis and oxidative stress, Histol. Histopathol., 23, 381

Niki, 2005, Lipid peroxidation: Mechanisms, inhibition, and biological effects, Biochem. Biophys. Res. Commun., 338, 668, 10.1016/j.bbrc.2005.08.072

2009, Lipid peroxidation of membrane phospholipids generates hydroxy-alkenals and oxidized phospholipids active in physiological and/or pathological conditions, Chem. Phys. Lipids, 157, 1, 10.1016/j.chemphyslip.2008.09.004

Fritz, 2013, An overview of the chemistry and biology of reactive aldehydes, Free Radic. Biol. Med., 59, 85, 10.1016/j.freeradbiomed.2012.06.025

Guo, 2003, Quantitative assessment of tyrosine nitration of manganese superoxide dismutase in angiotensin II-infused rat kidney, Am. J. Physiol. Heart Circ. Physiol., 285, H1396, 10.1152/ajpheart.00096.2003

Khan, 1998, 3-Nitrotyrosine in the proteins of human plasma determined by an ELISA method, Biochem. J., 330, 795, 10.1042/bj3300795

Dotan, 2004, Lipid peroxidation cannot be used as a universal criterion of oxidative stress, Prog. Lipid Res., 43, 200, 10.1016/j.plipres.2003.10.001

Lichtenberg, 2015, Oxidative stress, the term and the concept, Biochem. Biophys. Res. Commun., 461, 441, 10.1016/j.bbrc.2015.04.062

Le, 2014, Lipoprotein-associated oxidative stress: A new twist to the postprandial hypothesis, Int. J. Mol. Sci., 16, 401, 10.3390/ijms16010401

Morrow, 1998, Comparison of formation of D2/E2-isoprostanes and F2-isoprostanes in vitro and in vivo--effects of oxygen tension and glutathione, Arch. Biochem. Biophys., 353, 160, 10.1006/abbi.1998.0645

Tsikas, 2017, Assessment of lipid peroxidation by measuring malondialdehyde (MDA) and relatives in biological samples: Analytical and biological challenges, Anal. Biochem., 524, 13, 10.1016/j.ab.2016.10.021

Grimsrud, 2008, Oxidative stress and covalent modification of protein with bioactive aldehydes, J. Biol. Chem., 283, 21837, 10.1074/jbc.R700019200

Pizzimenti, 2013, Interaction of aldehydes derived from lipid peroxidation and membrane proteins, Front. Physiol., 4, 242, 10.3389/fphys.2013.00242

Slatter, 1998, Formation of a dihydropyridine derivative as a potential cross-link derived from malondialdehyde in physiological systems, FEBS Lett., 421, 180, 10.1016/S0014-5793(97)01554-8

Lamore, 2010, The malondialdehyde-derived fluorophore DHP-lysine is a potent sensitizer of UVA-induced photooxidative stress in human skin cells, J. Photochem. Photobiol. B, 101, 251, 10.1016/j.jphotobiol.2010.07.010

Palinski, 1994, ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum, Arterioscler. Thromb., 14, 605, 10.1161/01.ATV.14.4.605

Pratico, 1995, Cylooxygenase-dependent formation of the isoprostane, 8-epi prostaglandin F2α, J. Biol. Chem., 270, 9800, 10.1074/jbc.270.17.9800

Wang, 1995, Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man, J. Pharmacol. Exp. Ther., 275, 94

Lawson, 1998, Identification of two major F2 isoprostanes, 8,12-iso- and 5-epi-8,12-iso-isoprostane F2α-VI, in human urine, J. Biol. Chem., 273, 29295, 10.1074/jbc.273.45.29295

Barry, 1998, IPF2α-I: An index of lipid peroxidation in humans, Proc. Natl. Acad. Sci. USA, 95, 3449, 10.1073/pnas.95.7.3449

Li, 1999, Quantitative high performance liquid chromatography/tandem mass spectrometric analysis of the four classes of F2-isoprostanes in human urine, Proc. Natl. Acad. Sci. USA, 96, 13381, 10.1073/pnas.96.23.13381

Bessard, 2001, Determination of isoprostaglandin F2alpha type III in human urine by gas chromatography-electronic impact mass spectrometry. Comparison with enzyme immunoassay, J. Chromatogr. B Biomed. Sci. Appl., 754, 333, 10.1016/S0378-4347(00)00621-6

Davi, 2005, Lipid peroxidation in diabetes mellitus, Antioxid. Redox Signal., 7, 256, 10.1089/ars.2005.7.256

Monnier, 2006, Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes, JAMA, 295, 1681, 10.1001/jama.295.14.1681

Proudfoot, 2009, HDL is the major lipoprotein carrier of plasma F2-isoprostanes, J. Lipid Res., 50, 716, 10.1194/jlr.M800607-JLR200

Proudfoot, 2016, F2-isoprostanes in HDL are bound to neutral lipids and phospholipids, Free Radic. Res., 50, 1374, 10.1080/10715762.2016.1250262

Stafforini, 2006, Release of free F2-isoprostanes from esterified phospholipids is catalyzed by intracellular and plasmaplatelet-activating factor acetylhydrolases, J. Biol. Chem., 281, 4616, 10.1074/jbc.M507340200

Morrow, 1990, A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism, Proc. Natl. Acad. Sci. USA, 87, 9383, 10.1073/pnas.87.23.9383

Halliwell, 2010, Using isoprostanes as biomarkers of oxidative stress: Some rarely considered issues, Antioxid. Redox Signal., 13, 145, 10.1089/ars.2009.2934

Stiegel, 2015, Kidney injury biomarkers and urinary creatinine variability in nominally healthy adults, Biomarkers, 20, 436, 10.3109/1354750X.2015.1094136

Bauer, 2014, Pathophysiology of isoprostanes in the cardiovascular system: Implications of isoprostane-mediated thromboxane A2 receptor activation, Br. J. Pharmacol., 171, 3115, 10.1111/bph.12677

FitzGerald, 1996, Generation of 8-epiprostaglandin F2alpha by human monocytes. Discriminate production by reactive oxygen species and prostaglandin endoperoxide synthase-2, J. Biol. Chem., 271, 8919

Delannoy, 2010, Hypoxia-induced hyperreactivity of pulmonary arteries: Role of cyclooxygenase-2, isoprostanes, and thromboxane receptors, Cardiovasc. Res., 85, 582, 10.1093/cvr/cvp292

Reilly, 1996, Modulation of oxidant stress in vivo in chronic cigarette smokers, Circulation, 94, 19, 10.1161/01.CIR.94.1.19

Tsikas, 2012, Glutathione promotes prostaglandin H synthase (cyclooxygenase)-dependent formation of malondialdehyde and 15(S)-8-iso-prostaglandin F2α, FEBS Lett., 586, 3723, 10.1016/j.febslet.2012.09.001

Pilz, 2000, Measurement of free and bound malondialdehyde in plasma by high-performance liquid chromatography as the 2,4-dinitrophenylhydrazine derivative, J. Chromatogr. B Biomed. Sci. Appl., 742, 315, 10.1016/S0378-4347(00)00174-2

Wade, 1985, Quantitation of malondialdehyde (MDA) in plasma, by ion-pairing reverse phase high performance liquid chromatography, Biochem. Med., 33, 291, 10.1016/0006-2944(85)90003-1

Yu, 1986, High-performance liquid chromatography analysis of the thiobarbituric acid adducts of malonaldehyde and trans,trans-muconaldehyde, Anal. Biochem., 156, 326, 10.1016/0003-2697(86)90261-7

Moselhy, 2013, A specific, accurate, and sensitive measure of total plasma malondialdehyde by HPLC, J. Lipid Res., 54, 852, 10.1194/jlr.D032698

Cordis, 1998, High-performance liquid chromatographic peak identification of 2,4-dinitrophenylhydrazine derivatives of lipid peroxidation aldehydes by photodiode array detection, J. Chromatogr. A, 798, 117, 10.1016/S0021-9673(97)01161-8

Sobsey, 2016, Development and evaluation of a liquid chromatography–mass spectrometry method for rapid, accurate quantitation of malondialdehyde in human plasma, J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 1029–1030, 205, 10.1016/j.jchromb.2016.07.013

Tsikas, 2016, Development, validation and biomedical applications of stable-isotope dilution GC-MS and GC-MS/MS techniques for circulating malondialdehyde (MDA) after pentafluorobenzyl bromide derivatization: MDA as a biomarker of oxidative stress and its relation to 15(S)-8-iso-prostaglandin F2α and nitric oxide (NO), J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 1019, 95, 10.1016/j.jchromb.2015.10.009

Zelzer, 2013, Measurement of total and free malondialdehyde by gas–chromatography mass spectrometry—Comparison with high-performance liquid chromatography methology, Free Radic. Res., 47, 651, 10.3109/10715762.2013.812205

Verde, 2002, Use of N,N-dimethyl-p-phenylenediamine to evaluate the oxidative status of human plasma, Free Radic. Res., 36, 869, 10.1080/1071576021000005302

Ito, F., Ito, T., Suzuki, C., Yahata, T., Ikeda, K., and Hamaoka, K. (2017). The Application of a modified d-ROMs test for measurement of oxidative stress and oxidized high-density lipoprotein. Int. J. Mol. Sci., 18.

Tang, 2000, The mechanism of Fe2+-initiated lipid peroxidation in liposomes: The dual function of ferrous ions, the roles of the pre-existing lipid peroxides and the lipid peroxyl radical, Biochem. J., 352, 27, 10.1042/bj3520027

Rosenson, 2011, HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events, Clin. Chem., 57, 392, 10.1373/clinchem.2010.155333

Pirillo, 2013, High-density lipoprotein subfractions—What the clinicians need to know, Cardiology, 124, 116, 10.1159/000346463

Soran, 2015, Antioxidant properties of HDL, Front. Pharmacol., 6, 222, 10.3389/fphar.2015.00222

Motta, 1995, Physicochemical changes in human high-density lipoprotein (HDL) oxidized by gamma radiolysis-generated oxyradicals. Effect on their cholesterol effluxing capacity, Biochim. Biophys. Acta, 1255, 23, 10.1016/0005-2760(94)00211-G

Kontush, 2010, Antiatherogenic function of HDL particle subpopulations: Focus on antioxidative activities, Curr. Opin. Lipidol., 21, 312, 10.1097/MOL.0b013e32833bcdc1

Landmesser, 2014, High-density lipoprotein: Vascular protective effects, dysfunction, and potential as therapeutic target, Circ. Res., 114, 171, 10.1161/CIRCRESAHA.114.300935

Rasmiena, 2016, High density lipoprotein efficiently accepts surface but not internal oxidized lipids from oxidized low density lipoprotein, Biochim. Biophys. Acta, 1861, 69, 10.1016/j.bbalip.2015.11.002

Pandey, 2011, Biomarkers of oxidative stress in red blood cells, Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub., 155, 131, 10.5507/bp.2011.027

Nakagawa, 2009, Antioxidant effect of lutein towards phospholipid hydroperoxidation in human erythrocytes, Br. J. Nutr., 102, 1280, 10.1017/S0007114509990316

Ito, F., and Ito, T. Whole blood assay of oxidative stress by Fe-ROMs test, unpublished; manuscript in preparation.

Cade, 2008, Diabetes-related microvascular and macrovascular diseases in the physical therapy setting, Phys. Ther., 88, 1322, 10.2522/ptj.20080008

Kannel, 1979, Diabetes and cardiovascular risk factors: The Framingham study, Circulation, 59, 8, 10.1161/01.CIR.59.1.8

Nathan, 2005, Diabetes control and complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes, N. Engl. J. Med., 353, 2643, 10.1056/NEJMoa052187

Holman, 2008, 10-year follow-up of intensive glucose control in type 2 diabetes, N. Engl. J. Med., 359, 1577, 10.1056/NEJMoa0806470

Ceriello, 2009, Postprandial hyperglycemia and cardiovascular disease is the HEART2D study the answer?, Diabetes Care, 32, 521, 10.2337/dc08-2209

Stratton, 2000, Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study, BMJ, 321, 405, 10.1136/bmj.321.7258.405

Juutilainen, 2008, Similarity of the impact of type 1 and type 2 diabetes on cardiovascular mortality in middle-aged subjects, Diabetes Care, 31, 714, 10.2337/dc07-2124

Ciabattoni, 1999, In vivo formation of 8-iso prostaglandin F2α and platelet activation in diabetes mellitus: Effects of improved metabolic control and vitamin E supplementation, Circulation, 99, 224, 10.1161/01.CIR.99.2.224

Sampson, 2002, Plasma F2 isoprostanes: Direct evidence of increased free radical damage during acute hyperglycemia in type 2 diabetes, Diabetes Care, 25, 537, 10.2337/diacare.25.3.537

Chiarelli, 2003, Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: Role of interleukin-6 and disease duration, Circulation, 107, 3199, 10.1161/01.CIR.0000074205.17807.D0

Patrono, 2005, Isoprostane formation and inhibition in atherothrombosis, Curr. Opin. Pharmacol., 5, 198, 10.1016/j.coph.2004.11.003

Saisho, 2014, Glycemic variability and oxidative stress: A link between diabetes and cardiovascular disease?, Int. J. Mol. Sci., 15, 18381, 10.3390/ijms151018381

Dailey, 2007, Assessing glycemic control with self-monitoring of blood glucose and hemoglobin A1c measurements, Mayo Clin. Proc., 82, 229, 10.1016/S0025-6196(11)61003-3

DECODE Study Group, the European Diabetes Epidemiology Group (2001). Glucose tolerance and cardiovascular mortality: Comparison of fasting and 2-hour diagnostic criteria. Arch. Intern. Med., 161, 397–405.

Cavalot, 2006, Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: Lessons from the San Luigi Gonzaga Diabetes Study, J. Clin. Endocrinol. Metab., 91, 813, 10.1210/jc.2005-1005

Kodani, 2013, Effects of mitiglinide, a short-acting insulin secretagogue, on daily glycemic variability and oxidative stress markers in Japanese patients with type 2 diabetes mellitus, Clin. Drug Investig., 33, 563, 10.1007/s40261-013-0098-5

Yang, 2016, The Impact of Hypoglycemia on the Cardiovascular System: Physiology and Pathophysiology, Angiology, 67, 802, 10.1177/0003319715623400

Massin, 2010, Hypoglycemia-induced blood pressure elevation in patients with diabetes, Arch. Intern. Med., 170, 829, 10.1001/archinternmed.2010.98

Assaloni, 2005, Effects of S21403 (mitiglinide) on postprandial generation of oxidative stress and inflammation in type 2 diabetic patients, Diabetologia, 48, 1919, 10.1007/s00125-005-1849-5

Ohara, 2016, Relationship between daily and day-to-day glycemic variability and increased oxidative stress in type 2 diabetes, Diabetes Res. Clin. Pract., 122, 62, 10.1016/j.diabres.2016.09.025

Davignon, 2004, Role of endothelial dysfunction in atherosclerosis, Circulation, 109, III27, 10.1161/01.CIR.0000131515.03336.f8

Allen, 2014, Diabetes status differentiates endothelial function and plasma nitrite response to exercise stress in peripheral arterial disease following supervised training, J. Diabetes Complic., 28, 219, 10.1016/j.jdiacomp.2013.08.002

Valls, 2014, Essential hypertension and oxidative stress: New insights, World J. Cardiol., 6, 353, 10.4330/wjc.v6.i6.353

Davi, 1997, In vivo formation of 8-epi prostaglandin F2α is increased in hypercholesterolemia, Arterioscler. Thromb. Vasc. Biol., 17, 3230, 10.1161/01.ATV.17.11.3230

Keaney, 2003, Obesity and systemic oxidative stress: Clinical correlates of oxidative stress in the Framingham Study, Arterioscler. Thromb. Vasc. Biol., 23, 434, 10.1161/01.ATV.0000058402.34138.11

Ye, 2013, Mechanisms of insulin resistance in obesity, Front. Med., 7, 14, 10.1007/s11684-013-0262-6

Hurrle, 2017, The etiology of oxidative stress in insulin resistance, Biomed. J., 40, 257, 10.1016/j.bj.2017.06.007

Evans, 2003, Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction?, Diabetes, 52, 1, 10.2337/diabetes.52.1.1

Montezano, 2012, Reactive oxygen species and endothelial function--role of nitric oxide synthase uncoupling and Nox family nicotinamide adenine dinucleotide phosphate oxidases, Basic Clin. Pharmacol. Toxicol., 110, 87, 10.1111/j.1742-7843.2011.00785.x

Fleming, 2010, Molecular mechanisms underlying the activation of eNOS, Pflug. Arch., 459, 793, 10.1007/s00424-009-0767-7

Bauer, 2003, Compensatory phosphorylation and protein-protein interactions revealed by loss of function and gain of function mutants of multiple serine phosphorylation sites in endothelial nitric-oxide synthase, J. Biol. Chem., 278, 14841, 10.1074/jbc.M211926200

Montagnani, 2001, Insulin-stimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser1179, J. Biol. Chem., 276, 30392, 10.1074/jbc.M103702200

Rees, 1990, Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo, Br. J. Pharmacol., 101, 746, 10.1111/j.1476-5381.1990.tb14151.x

Ting, 1996, Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus, J. Clin. Investig., 97, 22, 10.1172/JCI118394

Tesfamariam, 1991, Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C, J. Clin. Investig., 87, 1643, 10.1172/JCI115179

Williams, 1998, Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo, Circulation, 97, 1695, 10.1161/01.CIR.97.17.1695

Sandoo, 2010, The endothelium and its role in regulating vascular tone, Open Cardiovasc. Med. J., 4, 302, 10.2174/1874192401004010302

Miyoshi, 2016, Assessment of arterial stiffness using the cardio-ankle vascular index, Pulse (Basel), 4, 11

Hofman, 2006, Arterial stiffness and risk of coronary heart disease and stroke: The Rotterdam Study, Circulation, 113, 657, 10.1161/CIRCULATIONAHA.105.555235

Kawano, 1999, Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery, J. Am. Coll. Cardiol., 34, 146, 10.1016/S0735-1097(99)00168-0

Beckman, 2001, Ascorbate restores endothelium-dependent vasodilation impaired by acute hyperglycemia in humans, Circulation, 103, 1618, 10.1161/01.CIR.103.12.1618

Ceriello, 2002, Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: Effects of short- and long-term simvastatin treatment, Circulation, 106, 1211, 10.1161/01.CIR.0000027569.76671.A8

Ceriello, 2008, Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients, Diabetes, 57, 1349, 10.2337/db08-0063

Risso, 2001, Intermittent high glucose enhances apoptosis in human umbilical vein endothelial cells in culture, Am. J. Physiol. Endocrinol. Metab., 281, E924, 10.1152/ajpendo.2001.281.5.E924

Azuma, 2006, Repetitive fluctuations in blood glucose enhance monocyte adhesion to the endothelium of rat thoracic aorta, Arterioscler. Thromb. Vasc. Biol., 26, 2275, 10.1161/01.ATV.0000239488.05069.03

Manzato, 1993, Lipoprotein abnormalities in well-treated type II diabetic patients, Diabetes Care, 16, 469, 10.2337/diacare.16.2.469

Lyons, 1997, Glycation, oxidation, and lipoxidation in the development of the complications of diabetes: A carbonyl stress hypothesis, Diabetes Rev. (Alex), 5, 365

Njajou, 2009, Association between oxidized LDL, obesity and type 2 diabetes in a population-based cohort, the Health, Aging and Body Composition Study, Diabetes Metab. Res. Rev., 25, 733, 10.1002/dmrr.1011

Nakhjavani, 2010, Serum oxidized-LDL is associated with diabetes duration independent of maintaining optimized levels of LDL-cholesterol, Lipids, 45, 321, 10.1007/s11745-010-3401-8

Tsimikas, 2009, Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race, apolipoprotein(a) isoform size and cardiovascular risk factors: Results from the Dallas Heart Study, Circulation, 119, 1711, 10.1161/CIRCULATIONAHA.108.836940

Miller, 1977, The Tromsø Heart Study: High-density lipoprotein and coronary heart disease: A prospective case-control study, Lancet, 1, 965, 10.1016/S0140-6736(77)92274-7

Ashen, 2005, Clinical practice: Low HDL cholesterol levels, N. Engl. J. Med., 353, 1252, 10.1056/NEJMcp044370

Barter, 2007, HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events, N. Engl. J. Med., 357, 1301, 10.1056/NEJMoa064278

Wang, 2003, Regulation and mechanisms of ATP-binding cassette transporter A1-mediated cellular cholesterol efflux, Arterioscler. Thromb. Vasc. Biol., 23, 1178, 10.1161/01.ATV.0000075912.83860.26

Sorrentino, 2010, Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy, Circulation, 121, 110, 10.1161/CIRCULATIONAHA.108.836346

Ragbir, 2010, Dysfunctional high-density lipoprotein and atherosclerosis, Curr. Atheroscler. Rep., 12, 343, 10.1007/s11883-010-0091-x

Farbstein, 2012, HDL dysfunction in diabetes: Causes and possible treatments, Expert Rev. Cardiovasc. Ther., 10, 353, 10.1586/erc.11.182

Duell, 1991, Nonenzymatic glycosylation of HDL and impaired HDL-receptor-mediated cholesterol efflux, Diabetes, 40, 377, 10.2337/diab.40.3.377

Zhou, 2008, Increased serum advanced glycation end products are associated with impairment in HDL antioxidative capacity in diabetic nephropathy, Nephrol. Dial. Transplant., 23, 927, 10.1093/ndt/gfm631

Zheng, 2004, Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease, J. Clin. Investig., 114, 529, 10.1172/JCI200421109

Holzer, 2011, Protein carbamylation renders high-density lipoprotein dysfunctional, Antioxid. Redox Signal., 14, 2337, 10.1089/ars.2010.3640

Ito, F., Sono, Y., Kondo, K., Ugi, S., Matsumoto, M., Maegawa, H., and Morino, K. Oxidized high-density lipoprotein is associated with vascular endothelial dysfunction in patients with type 2 diabetes mellitus, unpublished; manuscript in preparation.

Montezano, 2013, Angiotensin II, NADPH oxidase, and redox signaling in the vasculature, Antioxid. Redox Signal., 19, 1110, 10.1089/ars.2012.4641

Higashi, 2012, Endothelial dysfunction and hypertension in aging, Hypertens. Res., 35, 1039, 10.1038/hr.2012.138

Montezano, 2014, Reactive oxygen species, vascular noxs, and hypertension: Focus on translational and clinical research, Antioxid. Redox Signal., 20, 164, 10.1089/ars.2013.5302

Koya, 1998, Protein kinase C activation and the development of diabetic complications, Diabetes, 47, 859, 10.2337/diabetes.47.6.859

Volpe, 2018, Cellular death, reactive oxygen species (ROS) and diabetic complications, Cell Death Dis., 9, 119, 10.1038/s41419-017-0135-z

Tomino, 2011, AGE–RAGE interaction and oxidative stress in obesity related renal dysfunction, Kidney Int., 80, 133, 10.1038/ki.2011.86

Basta, 2005, At least 2 distinct pathways generating reactive oxygen species mediate vascular cell adhesion molecule-1 induction by advanced glycation end products, Arterioscler. Thromb. Vasc. Biol., 25, 1401, 10.1161/01.ATV.0000167522.48370.5e

Tan, 2002, Advanced glycation end products and endothelial dysfunction in type 2 diabetes, Diabetes Care, 25, 1055, 10.2337/diacare.25.6.1055

Bae, 2016, Obesity and glycemic control in patients with diabetes mellitus: Analysis of physician electronic health records in the US from 2009–2011, J. Diabetes Complic., 30, 212, 10.1016/j.jdiacomp.2015.11.016

Flock, 2011, Effects of adiposity on plasma lipid response to reductions in dietary saturated fatty acids and cholesterol, Adv. Nutr., 2, 261, 10.3945/an.111.000422

Farb, 2012, Arteriolar function in visceral adipose tissue is impaired in human obesity, Arterioscler. Thromb. Vasc. Biol., 32, 467, 10.1161/ATVBAHA.111.235846

Furukawa, 2004, Increased oxidative stress in obesity and its impact on metabolic syndrome, J. Clin. Investig., 114, 1752, 10.1172/JCI21625

Fujita, 2006, Systemic oxidative stress is associated with visceral fat accumulation and the metabolic syndrome, Circ. J., 70, 1437, 10.1253/circj.70.1437

Morelli, 2018, Metabolic syndrome components are associated with oxidative stress in overweight and obese patients, Arch. Endocrinol. Metab., 62, 309

Yokota, 2013, Systemic oxidative stress is associated with lower aerobic capacity and impaired skeletal muscle energy metabolism in patients with metabolic syndrome, Diabetes Care, 36, 1341, 10.2337/dc12-1161

Pradhan, 2001, C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus, JAMA, 286, 327, 10.1001/jama.286.3.327

Ford, 1999, Body mass index, diabetes, and C-reactive protein among U.S. adults, Diabetes Care, 22, 1971, 10.2337/diacare.22.12.1971

Festa, 2000, Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS), Circulation, 102, 42, 10.1161/01.CIR.102.1.42

Sesso, 2003, C-reactive protein and the risk of developing hypertension, JAMA, 290, 2945, 10.1001/jama.290.22.2945

Pearle, 2007, Elevated high-sensitivity C-reactive protein levels are associated with local inflammatory findings in patients with osteoarthritis, Osteoarthr. Cartil., 15, 516, 10.1016/j.joca.2006.10.010

Daghestani, 2015, Inflammatory biomarkers in osteoarthritis, Osteoarthr. Cartil., 23, 1890, 10.1016/j.joca.2015.02.009

Biswas, 2016, Does the interdependence between oxidative stress and inflammation explain the antioxidant paradox?, Oxid. Med. Cell Longev., 2016, 5698931, 10.1155/2016/5698931

Imhof, 2000, Association between C-reactive protein and features of the metabolic syndrome: A population-based study, Diabetes Care, 23, 1835, 10.2337/diacare.23.12.1835

Albert, 2003, Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score, Circulation, 108, 161, 10.1161/01.CIR.0000080289.72166.CF

Cottone, 2006, Relation of C-reactive protein to oxidative stress and to endothelial activation in essential hypertension, Am. J. Hypertens., 19, 313, 10.1016/j.amjhyper.2005.09.005

Kim, 2018, Age-specific determinants of pulse wave velocity among metabolic syndrome components, inflammatory markers, and oxidative stress, J. Atheroscler. Thromb., 25, 178, 10.5551/jat.39388

Verma, 2002, A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis, Circulation, 106, 913, 10.1161/01.CIR.0000029802.88087.5E